Silodosin Patent Expiration
Silodosin is Used for managing the signs and symptoms of benign prostatic hyperplasia (BPH). It was first introduced by Abbvie Inc
Silodosin Patents
Given below is the list of patents protecting Silodosin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rapaflo | US5387603 | 1,5,7-trisubstituted indoline compounds and salts thereof |
Dec 01, 2018
(Expired) | Abbvie |
| Rapaflo | US5403847 | Use of α1C specific compounds to treat benign prostatic hyperlasia |
Nov 13, 2012
(Expired) | Abbvie |
| Rapaflo | US5780485 | Use of α1c specific compounds to treat benign prostatic hyperplasia |
Nov 13, 2012
(Expired) | Abbvie |
| Rapaflo | US6015819 | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
Nov 13, 2012
(Expired) | Abbvie |
Silodosin's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List